NCT03916510 - Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 29, 2019

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions

Locally Advanced Rectal Cancer

Interventions

BIOLOGICAL

Enadenotucirev

Enadenotucirev is a live replicating oncolytic adenovirus; it is considered a BioSafety Level 1 (BSL-1) infectious substance.

DRUG

Capecitabine

Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.

RADIATION

Radiotherapy

50 Gy/25#

Trial Locations (4)

CF14 2TL

Velindre Cancer Centre, Cardiff

G12 0YN

Beatson West Of Scotland Cancer Centre, Glasgow

OX3 7LE

The Churchill Hospital, Oxford University Hospitals Trust, Oxford

SM2 5PT

Royal Marsden NHS Foundation Trust, Sutton